About: Sunitinib Malate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sunitinib Malate Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	Class
rdfs:label	Sunitinib Malate
rdfs:subClassOf	Tyrosine Kinase Inhibitor Angiogenesis Activator Inhibitor nodeID://b711327 nodeID://b711328 nodeID://b711329 nodeID://b711330 nodeID://b711331
Has_Free_Acid_Or_Base_Form	SUNITINIB
Has_Target	Receptors, Platelet-Derived Growth Factor Proto-Oncogene Proteins c-kit Vascular Endothelial Growth Factor Receptor-1 Tyrosine-Protein Kinase Receptor RET Fms-Related Tyrosine Kinase 3 Vascular Endothelial Growth Factor Receptor-3 Vascular Endothelial Growth Factor Receptor-2
Concept_In_Subset	FDA Established Names and Unique Ingredient Identifier Codes Terminology
Semantic_Type	Pharmacologic Substance
Preferred_Name	Sunitinib Malate
NSC_Code	736511
UMLS_CUI	C1700685
CAS_Registry	341031-54-7
Accepted_Therapeutic_Use_For	Gastrointestinal Stromal Tumor; Advanced Metastatic Renal Cell Carcinoma
In_Clinical_Trial_For	Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Neuro-Endocrine Tumors; Uterine Cancer; Angiosarcoma; Mesothelioma; Pancreatic Carcinoma; Breast Cancer; Colorectal Cancer; Undifferentiated Nasopharyngeal Carcinoma Acute myeloid leukemia; unresectable neuroendocrine tumor; malignant gastrointestinal stromal tumor; breast cancer; metastatic colorectal cancer; prostate cancer
FDA_UNII_Code	LVX8N1UT73
Contributing_Source	FDA
ALT_DEFINITION	A drug used to treat gastrointestinal stromal tumors (GIST) that have not responded to treatment with imatinib mesylate (Gleevec). SU011248 is also used to treat advanced kidney cancer and is being studied in the treatment of other types of cancer. It is a type of tyrosine kinase inhibitor, a type of vascular endothelial growth factor (VEGF) receptor inhibitor, and a type of angiogenesis inhibitor.NCI-GLOSS
PDQ_Open_Trial_Search_ID	299061
PDQ_Closed_Trial_Search_ID	299061
Chemical_Formula	C22H27FN4O2.C4H6O5
Legacy_Concept_Name	SU11248
FULL_SYN	Sunitinib MalatePTDCP32183 SUNITINIB MALATEPTFDALVX8N1UT73 Sunitinib MalatePTNCI SU11248PTNCI-GLOSSCDR0000492234 SutentPTNCI-GLOSSCDR0000492235 SU011248PTNCI-GLOSSCDR0000306520 SutentBRNCI SU11248CNNCI SU011248CNNCI Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)SNNCI sunitinib malatePTNCI-GLOSSCDR0000468779 sunitinibPTNCI-GLOSSCDR0000492233
DEFINITION	The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.NCI
code	C26673
is Has_Salt_Form of	SUNITINIB

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 116 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software